Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION After a boxed-warning proposal from the review division, complete-response-letter deficiency list is what RWE evidence-strategy director can touch in a biologics company planning a biosimilar pathway. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this CMC and Development Pathways file.

DECISION RWE evidence-strategy director in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. RWE evidence-strategy director can defend Proceed under protocol from complete-response-letter deficiency list after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge. 2. RWE evidence-strategy director cannot defend Proceed under protocol from complete-response-letter deficiency list; Pause the pathway is what the extract actually supports after a boxed-warning proposal from the review division. 3. A boxed-warning proposal from the review division never reached the population in complete-response-letter deficiency list — reopen intake, do not close to drop a secondary. 4. Two facts in complete-response-letter deficiency list after a boxed-warning proposal from the review division conflict for RWE evidence-strategy director; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a boxed-warning proposal from the review division. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read complete-response-letter deficiency list against a boxed-warning proposal from the review division and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (complete-response-letter deficiency list after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a biologics company planning a biosimilar pathway.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in complete-response-letter deficiency list, then the action for RWE evidence-strategy director - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Owner and next date for RWE evidence-strategy director in a biologics company planning a biosimilar pathway - What changes to drop a secondary if a boxed-warning proposal from the review division is later withdrawn